Pharmafile Logo

News and Press Releases

Acuitas Therapeutics to Showcase LNP Delivery Platform at Four Prestigious Conferences in November 2025

29 October 2025 -- British Columbia, Canada -- Acuitas Therapeutics, a global leader in lipid nanoparticle (LNP) delivery systems, today announced its participation in four upcoming conferences in November 2025....

Category: Biotechnology, Clinical Trials, Other, Pharmaceutical
Posted: November 11, 2025

Acuitas Therapeutics
info@acuitastx.com
6190 Agronomy Road, Suite 205. Vancouver, BC V6T 1Z3

Ocugen, Inc. and Kwangdong Pharmaceutical Co., Ltd. Complete License Agreement of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea

Upfront fees and near-term development milestone payments totaling up to $7.5 million Potential sales milestones of $180 million or more in first 10 years of commercialization Royalties equaling 25% of...

Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: September 15, 2025

Ocugen
11 Great Valley Parkway Malvern, PA 19355

CSL Behring and GKV-Spitzenverband Agree on Reimbursement Price for HEMGENIX® – Europe’s First Gene Therapy for Haemophilia B

2 April 2025 -- Marburg, Germany -- CSL Behring and the GKV-Spitzenverband (National Association of Statutory Health Insurance Funds) have successfully concluded negotiations on the reimbursement price of HEMGENIX. This...

Category: Other, Pharmaceutical
Posted: April 2, 2025

CSL
CSL Global Headquarters, 655 Elizabeth Street, Melbourne VIC 3000 Australia

Fondazione Telethon Submits US Biological License Application for Etuvetidigene Autotemcel Gene Therapy for the Treatment of Wiskott-Aldrich Sydrome

11 March 2025 -- Milan, Italy -- Fondazione Telethon, an Italian biomedical charity focused on rare genetic diseases, announced that it has submitted the Biologics License Application (BLA) for the...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 11, 2025

Fondazione Telethon
info@telethon.it
Via Poerio 14 - 20129 Milano

Vertex Announces UK MHRA Approval of ALYFTREK (Deutivacaftor/Tezacaftor/Vanzacaftor), a Once-Daily Next-in-Class CFTR Modulatorfor the Treatment of Cystic Fibrosis

Deutivacaftor/tezacaftor/vanzacaftor approved for people with cystic fibrosis 6 years and older with at least one responsive mutation in the CFTR gene, including additional mutations not previously approved with other CFTR...

Category: Drug Discovery, Other, Pharmaceutical
Posted: March 7, 2025

Vertex Pharmaceuticals

Boehringer Ingelheim and partners start clinical development of a first-in-class, inhaled gene therapy for people with cystic fibrosis

Ingelheim, Germany – Boehringer Ingelheim, IP Group, the UK Respiratory Gene Therapy Consortium (GTC)1 and OXB,1 today announce the start of LENTICLAIRTM 1, a Phase I/II trial of BI 3720931,...

Category: Biotechnology
Posted: February 24, 2025

Boehringer Ingelheim
Binger Strasse 173 55216 Ingelheim am Rhein

Glox Therapeutics Awarded Share of £3M Collaborative Discovery Programme Funding from Cystic Fibrosis Antimicrobial Resistance Syndicate

£500K grant to advance discovery and development of effective precision antibiotics targeting antimicrobial-resistant lung infections in people with cystic fibrosis Programme delivered by CF AMR Syndicate offers cross-sector collaboration and...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: January 21, 2025

Glox Therapeutics
info@gloxtherapeutics.com
11 The Square University Of Glasgow University Avenue Glasgow G12 8QQ

SEKISUI Completes £15.7 Million Expansion in cGMP Biopharma CDMO Capacity

Growth of UK facility will enable clinical-grade manufacturing of drug substances for range of biopharmaceutical products 14 November 2024 – Burlington, MA, USA – SEKISUI Diagnostics’ microbial CDMO business announces...

Category: Manufacturing and Packing
Posted: November 19, 2024

SEKISUI Diagnostics

Destiny Pharma initiates research to explore XF drug potential for CF

Study to investigate the potential of XF-73 to treat MRSA infection in people with cystic fibrosis 14 August 2024 -- Brighton, UK -- Destiny Pharma, a clinical stage biotechnology company...

Category: Biotechnology, Clinical Trials, Pharmaceutical
Posted: August 14, 2024

Destiny Pharma
pressoffice@destinypharma.com
Destiny Pharma plc, Sussex Innovation Centre, Science Park Square, Brighton, BN1 9SB UK

Enterprise Therapeutics appoints Dr Renu Gupta as chief medical officer and Dr Janet Hammond as non-executive director

Appointments bring additional respiratory and late clinical-stage drug development experience as company commences Phase 2a clinical trial of its lead asset 17 June 2024, Brighton, UK -: Enterprise Therapeutics Ltd...

Category: Biotechnology, Pharmaceutical
Posted: June 17, 2024

Enterprise Therapeutics
info@enterprisetherapeutics.com
Sussex Innovation Centre, University of Sussex, Science Park Square, Falmer, Brighton, BN1 9SB, UK

Enterprise Therapeutics publishes preclinical profile of ETD001, a novel inhaled ENaC blocker

Low doses of ETD001 demonstrate exceptionally long duration of action in sheep model of airway mucus clearance Report in Journal of Cystic Fibrosis discloses best-in-class profile of ETD001 ETD001 scheduled...

Category: Biotechnology, Clinical Trials, Drug Delivery, Drug Discovery, Pharmaceutical
Posted: June 12, 2024

Enterprise Therapeutics
info@enterprisetherapeutics.com
Sussex Innovation Centre, University of Sussex, Science Park Square, Falmer, Brighton, BN1 9SB, UK